Skip to content
  1. Home
  2. People
  3. Kara Kuritz
Kara Kuritz
Kara Kuritz
Partner — Antitrust
E: kkuritz@velaw.com T: +1.202.639.6598
VCard BIO PDF
Partner — Antitrust

Kara Kuritz

Kara Kuritz
Washington, D.C.
T: +1.202.639.6598
F: +1.202.879.8938

2200 Pennsylvania Avenue NW
Suite 500 West
Washington, D.C. 20037

E: kkuritz@velaw.com
VCard BIO PDF
Kara Kuritz

Kara Kuritz is a partner in Vinson & Elkins’ Antitrust practice. Her practice focuses on assessing antitrust risk in mergers and acquisitions, advising clients on how to navigate any antitrust risk, and working to ensure clients comply with US and global premerger notification requirements. Kara advocates on behalf of clients before the Federal Trade Commission, Antitrust Division of the Department of Justice, and state regulators in inquiries or investigations into mergers, acquisitions, or business conduct and policies. She also provides antitrust counseling on issues such as diligence and pre-closing conduct, information sharing, competitor collaborations, and interlocking directorates.

Kara previously served as the US Department of Justice Antitrust Division’s Hart-Scott-Rodino Act (HSR Act) Specialist. At the DOJ, Kara advised the Antitrust Division on application of the HSR Act, interlocking directorate issues, and antitrust policy issues. She liaised on behalf of the Antitrust Division with the FTC on HSR Act regulations, rulemakings, guidance, and enforcement actions. Kara also worked as a law clerk in the FTC’s Bureau of Competition.

Experience Highlights

  • Denbury Inc. in its $4.9 billion sale to ExxonMobil

  • PureWest Energy in its $1.84 billion merger with PW Picasso Buyer, a newly formed entity sponsored by a private consortium of family offices and financial institutions

  • Unanet and JMI Equity in its new round of strategic investment from Onex

  • Nutrabolt in its announced strategic partnership with Keurig Dr Pepper

  • PTC in its proposed acquisition of ServiceMax for approximately $1.46 billion

  • TA in its strategic growth investment in Technosylva

  • Acelyrin in its $300 million Series C financing round

  • Medical Properties Trust in its acquisition of Springstone for $950 million

  • Astorg Partners in its investment in the $500 million financing round of EcoVadis

  • Frazier Healthcare Partners in its sale of Parata Systems to Becton Dickinson & Co. for $1.525 billion

  • Clique Brands in its sale of Who What Wear to Future Publishing

  • ModeX Therapeutics in its sale to OPKO Health for $300 million

  • Biocon Biologics in its acquisition of Viatris for approximately $3.3 billion

  • CSafe Global in its acquisition of Softbox Systems

  • Innovium in its acquisition by Marvell Technology for $1.1 billion

  • G Squared in its $1.1 billion definitive business combination agreement with Transfix Inc.

Credentials

  • George Mason University School of Law, J.D. cum laude, 2008
  • Washington & Jefferson College, B.A. summa cum laude, 2004
  • Recommended Lawyer for Merger Control and FinTech by The Legal 500 2021 and 2022
  • U.S. Department of Justice, The John Marshall Award for Outstanding Legal Achievement for Support of Litigation, 2019
  • U.S. Department of Justice, Antitrust Division Award of Distinction, 2015 and 2017
  • Member: American Bar Association Antitrust Section; DC Bar Association; New York State Bar Association
  • District of Columbia
  • New York
  • Quoted, “FTC Investigation into Musk’s HSR Compliance Would Focus on Intent, Ex-DOJ Lawyer Says” Global Competition Review, May 2022
  • Author, “Unpacking the Proposed HSR Rule Changes,” The Exchange by the American Bar Association, December 2020
  • Quoted, “Private Equity Deals Face More Antitrust Scrutiny Under Proposal,” Bloomberg Law, November 2020
  • Co-author, “An Antitrust Roadmap for Private Equity Investment,” Antitrust by the American Bar Association, August 2020
  • Co-author, “USA Chapter, “Merger Control 2020,” Global Legal Insights, July 2020
  • Co-author with S. Sher, “The Innovation Costs of a Flawed Patent System,” MLex Magazine, October-December 2011
  • Co-author with S. Silber, “Product Switching in the Pharmaceutical Industry: Ripe for Antitrust Scrutiny?” Journal of Generic Medicines, January 12, 2010

Speaking Engagements

  • Speaker, “Healthcare Transactions, Antitrust Fundamentals,” American Health Law Association, April 2022
  • Speaker, “Fundamentals of Health Law, Recent Developments in Antitrust All Antitrust Lawyers Should Know,” American Health Law Association, November 2021
  • Speaker, “Antitrust Fundamentals for Health Lawyers,” American Health Law Association, November 2020
  • Speaker, “Unpacking the Proposed HSR Rule Changes,” ABA Section of Antitrust Law Insurance & Financial Services Committee, October 2020
  • Speaker, “Private Equity Planning for Post COVID-19: An Antitrust Roadmap for PE Investment,” Goodwin Webinar, July 2020
  • Speaker, “Life Sciences Deals & Antitrust in the Age of COVID-19,” Goodwin Webinar, May 2020
  • Speaker, ABA Section of Antitrust Law Merger Practice Workshop, October 2018
  • Speaker, ABA Section of Antitrust Law Merger Practice Workshop, September 2017
  • Speaker, “HSR Exemptions: Running Out of Gas?” American Bar Association Section of Antitrust Law Spring Meeting, March 2017
  • Speaker, “Mitigating Antitrust Risks in Mergers & Acquisitions Transactions: What Every Firm Needs to Know in 2015,” Knowledge Group Webcast, June 2015
  • Speaker, “Getting Back to the Hart-Scott-Rodino Basics,” American Bar Association Section of Antitrust Law Program, November 20, 2013

News & Insights

Deals & Cases
Atlas Energy Solutions Inc. to Acquire Hi-Crush Inc.
February 27, 2024
Insight
2024 Annual Updates to the United States Pre-Merger Notification (HSR Act) and Interlocking Directorates Thresholds

V&E Antitrust Update

Regulatory Roundup
January 24, 2024
Insight
2023 Chemicals & Energy Antitrust Report
Regulatory Roundup
January 11, 2024
Insight
FTC and DOJ Release New Merger Guidelines

V&E Antitrust Update

Regulatory Roundup
December 20, 2023